Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
April 08, 2024 08:30 ET
|
Longeveron
CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
Intelligencia AI Awarded U.S. Patent for Its Accurate and Transparent Probability of Drug Success Assessments
April 02, 2024 13:43 ET
|
Intelligencia AI
Health tech company pioneers de-risking clinical development through patented algorithms, technology and use of artificial intelligence
Intelligencia AI Ranks No. 90 on Inc. Magazine’s List of the Northeast Region’s Fastest-Growing Private Companies
March 20, 2024 09:18 ET
|
Intelligencia AI
Inc. magazine recently revealed that Intelligencia AI, a provider of AI-powered decision-making solutions for the pharmaceutical industry, ranks No. 90.
Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029: 800+ Bispecific Candidates Currently in Active Clinical Development
March 18, 2024 05:16 ET
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's...
Global Contract Research Organization Services Market Analysis & Forecast to 2023-2033: Pharmaceutical Giants Ramp Up Investments Amidst Rising Chronic Disease Burden
March 13, 2024 12:01 ET
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Global Contract Research Organization Services Market Analysis & Forecast to 2023-2033: Market By Service; By Application; By End-user; and By...
Global DLL3 Targeted Therapy Market Research Report 2024 - Innovations, Opportunities, Market Trends & Clinical Trials Insights
February 01, 2024 03:16 ET
|
Research and Markets
Dublin, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
Imutex's FLU-v Emerging Drug Insights and Market Forecasts, 2019-2023 and 2023-2032: Focus on United States,Germany, France, Italy, Spain, United Kingdom, and Japan
January 31, 2024 04:06 ET
|
Research and Markets
Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The "FLU-v Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
VBI-1901 Drug and Market Analysis Report 2023-2032: Mechanism of Action, Clinical Trials, Collaborations, and Market Projections for a Promising GBM Therapy
January 30, 2024 10:59 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "VBI-1901 Emerging Drug Insight and Market Forecast to 2032" report has been added to ResearchAndMarkets.com's offering. This report provides an...
MGB-BP-3 Drug and Market Analysis 2023-2032: A Promising Treatment for Clostridium Difficile Infection (CDI)
January 30, 2024 10:54 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "MGB-BP-3 Emerging Drug Insight and Market Forecast to 2032" report has been added to ResearchAndMarkets.com's offering. This report provides an...
MPH966 (Alvelestat) Drug Insight with Market Projections to 2032: A Novel Therapy Under Development for Bronchiolitis Obliterans Syndrome (BOS)
January 30, 2024 10:51 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "MPH966 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report offers an in-depth...